



Patent  
030727.0037.CIP1 #7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Paul D. Van Poelje, *et al.*

Serial No.: 09/900,364

Filed: July 5, 2001

For: COMBINATION OF FBPA  
INHIBITORS AND ANTIDIABETIC  
AGENTS USEFUL FOR THE  
TREATMENT OF DIABETES

)  
) Group Art Unit: 1623  
)  
) Examiner: To be assigned  
)  
)  
)  
)  
)  
)  
)

RECEIVED  
MAR 26 2003  
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In compliance with the Applicant's duty under 37 CFR § 1.56, the following information is brought to the attention of the Examiner. The items are listed on the attached form PTO/SB/08A and copies are enclosed for the convenience of the Examiner.

The items identified in this Information Disclosure Statement (IDS) may or may not be "material" pursuant to 37 CFR § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

3-18-03  
Date of Deposit

Megan Massey  
Name of Person Mailing Paper  
Megan Massey  
Signature of Person Mailing Paper

art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this IDS shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

The attached IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c) and is further authorized to charge any fee required by the filing of these papers to Paul, Hastings, Janofsky & Walker's Deposit Account No. **50-2613**.


Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated: 3/18/03

By: Diana L. Bush  
Diana L. Bush, Ph.D.  
Reg. No. 51,109

**PAUL, HASTINGS, JANOFSKY & WALKER LLP**  
12390 El Camino Real  
San Diego, CA 92130-2081  
Telephone: (858) 720-2500  
Facsimile: (858) 720-2555



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |                  |                          |                    |
|---|------------------|--------------------------|--------------------|
| Substitute for form 1449A/PTO   |                  | <b>Complete if Known</b> |                    |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |                  | Application Number       | 09/900,364         |
|   |                  | Filing Date              | July 5, 2001       |
|   |                  | First Named Inventor     | Paul D. Van Poelje |
|   |                  | Group Art Unit           | 1623               |
|   |                  | Examiner Name            | To be assigned     |
| Attorney Docket Number  | 030727.0037.CIP1 |                          |                    |
| Sheet   | 1                | of                       | 1                  |

RECEIVED

MAR 26 2003

TECH CENTER 1600/2900

| U.S. PATENT DOCUMENTS |                          |                      |                                      |  |  |  |
|-----------------------|--------------------------|----------------------|--------------------------------------|--|--|--|
| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | U.S. Patent Document |                                      | Name of Patentee or Applicant<br>of Cited Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |                          | Number               | Kind Code <sup>2</sup><br>(if known) |  |  |  |
|                       |                          |                      |                                      |  |  |  |

| FOREIGN PATENT DOCUMENTS |                          |                         |                     |                                      |   |  |  |                |
|--------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|--|--|----------------|
| Examiner<br>Initials*    | Cite<br>No. <sup>1</sup> | Foreign Patent Document |                     |                                      | Name of Patentee or<br>Applicant of Cited<br>Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear | T <sup>6</sup> |
|                          |                          | Office <sup>3</sup>     | Number <sup>4</sup> | Kind Code <sup>5</sup> (if<br>known) |   |  |  |                |
|                          | AA                       | WO                      | 90/09163            |                                      | Gensia Pharma   | 08-23-1990   |  |                |
|                          | AB                       | WO                      | 00/38666            |                                      | Metabasis<br>Therapeutics                             | 07-06-2000   |  |                |
|                          | AC                       | WO                      | 02/00673            |                                      | Rademacher, et al.                                    | 01-03-2002   |  |                |

| NON PATENT LITERATURE DOCUMENTS |                          |   |  |  |                |
|---------------------------------|--------------------------|---|--|--|----------------|
| Examiner<br>Initials*           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |  | T <sup>2</sup> |
|                                 |                          |   |  |  |                |
|                                 |                          |   |  |  |                |
|                                 |                          |   |  |  |                |
|                                 |                          |   |  |  |                |

|                       |                    |
|-----------------------|--------------------|
| Examiner<br>Signature | Date<br>Considered |
|-----------------------|--------------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.